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ABSTRACT
Age-related macular degeneration (AMD), is the leading cause of blind registration in the
Western World among individuals 65 years or older. Early AMD, a clinical state without overt
functional loss, is said to be present clinically when yellowish deposits known as drusen and/or
alterations of fundus pigmentation are seen in the macular retina. Although the etiopathogen-
esis of AMD remains uncertain, there is a growing body of evidence in support of the view that
cumulative oxidative damage plays a causal role. Appropriate dietary antioxidant supplemen-
tation is likely to be beneficial in maintaining visual function in patients with AMD, and pre-
venting or delaying the progression of early AMD to late AMD. The Carotenoids in Age-Related
Maculopathy (CARMA) Study is a randomized and double-masked clinical trial of antioxidant
supplementation versus placebo in 433 participants with either early AMD features of sufficient
severity in at least one eye or any level of AMD in one eye with late AMD (neovascular AMD
or central geographic atrophy) in the fellow eye. The aim of the CARMA Study is to investigate
whether lutein and zeaxanthin, in combination with co-antioxidants (vitamin C, E, and zinc), has
a beneficial effect on visual function and/or prevention of progression from early to late stages
of disease. The primary outcome is improved or preserved distance visual acuity at 12 months.
Secondary outcomes include improved or preserved interferometric acuity, contrast sensitivity,
shape discrimination ability, and change in AMD severity as monitored by fundus photography.
This article outlines the CARMA Study design and methodology, including its rationale.
INTRODUCTION
Age-related macular degeneration (AMD), previously also
known as age-related maculopathy, is the term used to describe
a spectrum of ageing changes in the macular retina of the eyes of
older adults. In the early stages a large proportion of older adults
have yellowish deposits known as drusen and alterations of fun-
dus pigmentation in the macular retina. This is known as early
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AMD. In a significant proportion of eyes exhibiting early AMD
there is progression through intermediate (more severe levels
of drusen and pigmentary irregularities) to late stages with dys-
function and death of photoreceptors secondary to an atrophic
(geographic atrophy, GA) and/or a neovascular (choroidal neo-
vascularization, CNV) event. These late stages are commonly
referred to as late AMD. Currently, late AMD is the leading
cause of blind registration in Western countries among individ-
uals 65 years and older,1−3 with CNV accounting for 90% of
these cases.4,5
In the future, the prevalence and incidence of AMD is ex-
pected to rise because of an increase in life expectancy, and
the consequential demographic shift towards an elderly popu-
lation will have implications for the socio–economic impact of
this disease.6,7 Currently available therapeutic interventions for
this condition are largely aimed at preservation of presenting
visual acuity (VA). 8−11 Although a significant proportion of pa-
tients may achieve some visual gain with the novel inhibitors
of vascular endothelial growth factor, complete restoration of
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discriminant visual function is only achieved in small propor-
tions of those treated.12,13 Moreover, there is no available treat-
ment for atrophic AMD. There is no doubt that effect of late
AMD on the activities of daily living, self-care, emotional well
being, and overall quality of life are important, and that these
are related to disease severity.14−19 Therefore, prevention or de-
lay of early to late manifestations represents the best means of
limiting the impact of this degenerative disorder on visual health
and quality of life in the elderly population.
While the exact etiopathogenesis of the disorder remains un-
certain, there is a growing body of evidence that cumulative ox-
idative damage may play a causal role.20,21 Oxidative damage
refers to tissue injury by reactive oxygen intermediates, which
are unstable molecules generated in cells as a by-product of
oxygen metabolism, and, additionally, in the retina, by pho-
tochemical reactions between light and oxygen. Consequently,
antioxidant supplementation could play an important role in pre-
venting the development of AMD, or delaying the progression
from early to late disease.
STUDY RATIONALE
One of the unique features of the primate macula is the pres-
ence of high concentrations of the xanthophylls, lutein (L) and
zeaxanthin (Z), which gives it its eponymous yellow color. To-
gether, these two xanthophylls are referred to as macular pigment
(MP).22 MP peaks in the central 1 to 2 degrees of the fovea, and
declines to optically negligible levels by 5 to 10 degrees radial
eccentricity.23 Of note, MP cannot be synthesized de novo, and
is derived entirely from diet.
Macular pigment is purported to prevent or retard the devel-
opment or progression of AMD because of its ability to absorb
blue light at the prereceptorial level, and because of its capac-
ity to quench reactive oxygen intermediates via its powerful
Table 1. Human Interventional Studies Investigating the Role of Supplemental L on Visual Function in Age-Related Macular Degeneration
Study/Author Supplement Duration of
(Year of publication) Design Participants (n) given/dose study Outcome
Richer et al. (1999) Case-series AMD patients (14) 14 mg L/day 3–12 months Improvement in visual
acuity, and several other
parameters of visual
function
Massacesi et al. (2001) Randomized,
placebo-controlled
Early AMD patients (50) 15 mg L/day 18 months Improvement in visual
acuity
Olmedilla et al. (2001) Case-series AMD patients (5) 15 mg L/day 13 months Improvement in visual
acuity, and glare
sensitivity
LAST (2004) Randomized,
placebo-controlled
AMD patients (90) 10 mg L/day 12 months Improvement in visual
acuity, and several other
parameters of visual
function
Barlett et al. (2007) Randomized,
placebo-controlled
Early and late AMD patients (25) 6 mg L/day 9 months No statistically significant
improvement in contrast
sensitivity function
LAST: Lutein Antioxidant Supplementation Trial.
L: Lutein.
antioxidant activity.20,21 Furthermore, it has been observed that
increased intake of dietary L and Z results in the augmenta-
tion of MP,24 consistent with the possibility that appropriate di-
etary supplementation or modification would confer protection
against development and/or progression of AMD.
The Age-Related Eye Disease Study (AREDS) has investi-
gated the role of multiple antioxidants, namely vitamins A,C,
and E and zinc, and demonstrated that treatment reduces the rel-
ative risk of disease progression to late AMD by 25% and results
in odds reduction of 27% for visual acuity loss.25 These benefi-
cial effects were mainly observed in the fellow eyes of a subset
of participants who had late stage AMD in the contralateral eye.
Noteworthy, too, was the protective effect in those participants
with intermediate stages of AMD in both eyes.
To date, five interventional studies have investigated the role
of L supplementation in AMD patients (Table 1),26−30 and the
data from four of these demonstrated improvements in acu-
ity and/or other parameters of visual function in the treatment
groups.27−30 Although the statistical power of these studies is
limited by their small sample sizes (n ≤ 90), they are, nonethe-
less, encouraging. More recently Chong and colleagues under-
took a systematic review and meta-analysis of dietary antiox-
idants and supplements, and questioned the value of primary
prevention.31 However, the findings of AREDS in terms of sec-
ondary prevention, particularly in the fellow eyes of patients
with advanced disease in the contralateral eye, raises intriguing
questions on the potential benefits of supplemental antioxidants.
Furthermore, a number of well-conducted population-based
studies employing longitudinal study design have suggested that
high levels of dietary antioxidants, specifically L and Z, may
have protective and beneficial effects in retarding progression to
advanced AMD (Table 2). Lutein and Z were not included in the
AREDS formulation because they were not commercially avail-
able in supplement form at the inception of that study. Further,
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Table 2. Observational Studies Examining the Relationship between Dietary and/or Serum Levels of Antioxidants and Risk of AMD
Study/Author No. of Antioxidants examined
(Year of publication) Design participants (Diet or serum) Conclusion
Eye-Disease Case
Control Study (1994)
Case-control 356 cases 520
controls
L, Z, lycopene, α and β
carotene, β
cryptoxanthin, retinol,
vitamin A, C, and E (diet)
Subjects with the highest quintile of carotenoid intake
had a 43% lower risk of AMD when compared with
those in the lowest quintile. Furthermore, of the
carotenoids, L and Z, which are primarily obtained
from dark green leafy vegetables, were most
strongly associated with a reduced risk of AMD (p for
trend = .001).
Beaver Dam Eye Study
1998)
Population-based 4926 L, Z, lycopene, α and β
carotene, β
cryptoxanthin, vitamin E,
C, and zinc (diet)
A significant (but modest) inverse association was
observed between dietary intakes of pro-vitamin A
carotenoids (and vitamin E) and the incidence of
large drusen. Similarly, a high level of dietary zinc
was associated with lower incidence of pigmentary
abnormalities.
National Health And
Nutrition Examination
Survey III (2001)
Cross-sectional 8,222 L, Z, and other carotenoids
(diet and serum)
A higher level of L and Z in the diet was associated
with lower risk of pigmentary abnormalities and of
late AMD in the youngest age groups at risk for
developing early or late AMD, after adjustment for
age, gender, alcohol use, hypertension, smoking,
and body mass index.
Snellen et al. (2002) Case-control 72 cases
66 controls
L, Z, and other
antioxidants (diet)
Subjects with low intake of dietary L and other
antioxidants exhibited a higher prevalence of
neovascular AMD when compared with subjects with
high dietary intake of these nutrients.
Gale et al. (2003) Cross-sectional 380 L, and Z (serum) Subjects with lowest concentrations of serum Z had a
two-fold increase in risk of AMD when compared
with those with the highest concentrations of this
carotenoid in the serum.
Rotterdam Study
(2005)
Population-based 4170 L, Z, lycopene, α and β
carotene, β
cryptoxanthin, vitamin A,
C, E, iron, and zinc (diet)
Dietary intake of vitamin E and zinc was inversely
associated with incident AMD. Furthermore, an
above-median intake of these nutrients, in
combination with beta-carotene and vitamin C, was
associated with a 35% reduced risk for AMD.
Pathologies Oculaires
Liees a‘ l’Age Study
(2006)
Population-based 899 L, Z, lycopene,
dehydro-lutein, α and β
carotene, and β
cryptoxanthin (serum)
Subjects with high serum L plus Z had a 79% reduced
risk of AMD when compared with subjects with low
serum L plus Z, and this inverse association was
particularly strong for serum Z.
The Carotenoids in
Age-Related Eye
Disease Study
(2006)
Population-based 1787 L, Z, β carotene, omega-3
fatty acids, β
cryptoxanthin, α and γ
tocopherols, vitamin C
and E, and zinc (diet)
There was no statistically significant difference in the
prevalence of intermediate AMD among subjects
with high and low intake of dietary L plus Z. However,
limiting analyses to women younger than 75 years
with stable intake of L plus Z (without a history of
chronic diseases that are often associated with diet
changes), revealed a reduced risk of this subtype of
AMD in association with a high dietary intake of
these antioxidants.
Age-Related Eye
Disease Study
(2007)
Case-control 4519 L, Z, lycopene, α and β
carotene, β
cryptoxanthin, retinol,
vitamin A, C, and E (diet)
A high dietary intake of L and Z was independently
associated with decreased likelihood of having
neovascular AMD, geographic atrophy, and large
and extensive drusen.
Blue Mountains Eye
Study (2007)
Population-based 2454 L, Z, lycopene, α and β
carotene, β
cryptoxanthin, vitamin A,
C, E, iron, and zinc (diet)
Subjects in the highest tertile of dietary intake of L and
Z had a reduced risk of neovascular AMD, whereas
those with above median intakes of these
carotenoids in the diet had a reduced risk of indistinct
soft or reticular drusen. In addition, a protective
influence of dietary zinc against AMD was observed.
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AREDS did not measure subtle differences in visual function
between the various intervention groups following antioxidant
supplementation. Thus there was an obvious need for controlled
clinical trials with L and Z included in the test formulation. We
hypothesized that reduction of oxidative stress at the level of the
RPE could potentially improve function. It was our view that the
detection of differences in visual function between intervention
groups would provide both a better understanding of the patho-
genesis, and add to the evidence base for the use of antioxidants
in preventing progression of early or intermediate to late AMD.
Therefore, the Carotenoids in Age-Related Maculopathy
(CARMA) Study, a randomized controlled clinical trial, was de-
veloped to test the hypothesis that a combination of antioxidant
vitamins, including L and Z, would be beneficial in maintaining
visual function and reducing the risk of progression to a more
severe morphological state. The rationale for adding L and Z to
the antioxidants (already proven to have a beneficial effect in
the AREDS Study) are two-fold: first, L and Z exhibit the ideal
anatomic, biochemical, and optical properties to limit (photo)
oxidative damage at the macula; second, carotenoids act syner-
gistically with other antioxidants to exert antioxidant effect.32
STUDY DESIGN
The CARMA Study is a randomized and double-masked clin-
ical trial of antioxidant supplementation versus placebo in 433
Caucasian AMD participants aged 50 years and above, who
are recruited at two clinical centers in Ireland (Waterford and
Belfast). Participants must have either early AMD features of
sufficient severity in at least one eye or any level of AMD in
one eye and advanced AMD (neovascular AMD or central GA)
in the fellow eye. All enrolled participants will be followed un-
til the last participant has completed one year of follow-up or
until the Data and Safety Monitoring Committee (DSMC) has
recommended earlier termination of the trial.
An overview of the administrating and coordinating infras-
tructures of the CARMA Study is given in Figure 1. The study is
approved by the Waterford Research Ethics Committee, and by
the Office for Research Ethics Committees in Northern Ireland.
The CARMA Study is registered with a clinical trial database
(International Standard Randomized Controlled Trial Number:
9455760).
AIMS OF THE STUDY
The principal aim of the CARMA Study is to investigate the
potential efficacy of L and Z, in combination with key vitamins
and minerals, on psychophysical measures of vision namely dis-
tance visual acuity (DVA), contrast sensitivity, photopic inter-
ferometric acuity, and shape discrimination. Secondary aims are
to examine the potential efficacy of the CARMA preparation in
delaying or retarding the morphological progression of early
AMD. The CARMA Study will also measure MP levels, and
serum concentrations of L and Z, in response to supplementa-
tion with the macular carotenoids.
SAMPLE SIZE AND POWER
CONSIDERATION
It is hypothesized that treatment with CARMA preparation
will result in either maintained function or improved function
while treatment with placebo will result in decreasing function.
The original study design employed photopic interferometric
acuity as the primary outcome variable. However, we encoun-
tered several problems in the consistency and reliability of this
measurement technique, and, therefore, following the DSMC
recommendations during its meeting in October 2005, the pri-
mary outcome measure was changed from photopic interferom-
etry to DVA. The study sample size was also increased in order
to take into account the change in the primary outcome mea-
sure. The revised protocol was approved by the Research Ethics
Committee at both the clinical centers.
The revised sample size calculations estimated that a sample
size of 500 participants with 5% alpha (2 sided test) will have
90% power to detect a 0.04 (2 logMAR letters) difference in
DVA assuming that standard deviation of the change in DVA
within a participant is 0.13 (6.5 logMAR letters) and that there
would be a 10% attrition rate. The study duration was extended
as a result of increase in the sample size.
RECRUITMENT STRATEGIES
Study awareness campaigns consisting of the distribution of
leaflets and posters along with presentations describing CARMA
are conducted at both sites. Potential participants are sent a let-
ter of invitation along with the study information leaflet (ex-
plaining the background and rationale for the CARMA Study)
containing contact details of the study staff. No financial in-
centives are offered to the participants;33 however, costs of
transportation to and from the study center are provided, where
requested.
All potential participants who expressed a willingness and
desire to participate in the CARMA Study are screened at a
study clinic where informed consent is obtained. Following ver-
ification of eligibility (Table 3), all participants are randomized
to one of the two groups. The CARMA preparation is provided
in numbered containers and the participant is instructed to take
one tablet twice daily. The first participant in the CARMA Study
was enrolled in July 2004, and new recruitments continued un-
til April 2007 to achieve the revised sample size. All enrolled
participants will be followed until the last participant has com-
pleted 1 year of follow-up, and, therefore, the study concluded
on April 2008. Also, participants who are recruited early on will
have the opportunity to be followed up for a maximum of 36
months.
The baseline/screening visit consists of four separate parts
(informed consent, clinical examination, questionnaire, and ran-
domization), and takes approximately 2–3 hours per participant.
The study is conducted in accordance with the principles set forth
in the Declaration of Helsinki.
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Figure 1. The CARMA Organization.
CLINICAL EXAMINATION
The clinical assessment was conducted by either an ophthal-
mologist or optometrist, supported by a study nurse, and con-
sisted of ophthalmic and systemic examination.
Ophthalmic examination
Distance visual acuity
Best-corrected DVA is determined using retro-illuminated
Early Treatment Diabetic Retinopathy Study (ETDRS, Preci-
sion Vision, USA) charts viewed at 4-m distance with room
lights turned off. After refracting the participant with ETDRS
“R” chart, using a combination of objective and subjective re-
fraction, the best corrected VA for each eye is measured with the
standard ETDRS protocol.34,35 If VA is worse than 0.8 logMAR,
i.e. fewer than 15 letters are read correctly at 4-m distance, mea-
surement of VA is repeated at 1-m distance. During recording of
vision on a score-sheet, each letter read correctly by the partici-
pant is encircled whereas those letters identified incorrectly are
crossed.
Photopic interferometric acuity (Retinal acuity)
Interferometry is performed under photopic conditions us-
ing a white light interferometer (Lotmar Visometer, Bern,
Switzerland).36 A total of 20 readings of the threshold spatial
frequency are made (5 for each orientation with the stimuli pre-
sented randomly) and the mean value calculated. The Purkinje
image of the green light on the cornea is monitored throughout
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Table 3. Inclusion and Exclusion Criteria for the CARMA Study
Inclusion criteria
• Age 50 years or older.
• Either gender.
• Able to give informed consent, make the required study visits, and
adhere to the protocol.
• Fundus characteristics:
Group 1-Participants with CNV or central GA in one eye, and any level
of AMD in the fellow eye with a best-corrected VA of 0.3 logMAR or
better.
Group 2-Participants with early AMD features of sufficient severity in at
least one eye. AMD features of sufficient severity are soft distinct or
indistinct drusen > 20 or if fewer than 20 soft drusen, focal hyper
pigmentation must be present. Best-corrected VA in the study eye
must be 0.3 logMAR (Snellen equivalent: 6/12) or better. Both eyes
of a participant may be eligible for inclusion into the study.
Exclusion Criteria
Systemic conditions
• History of any life threatening or terminal medical condition, such as
malignant disorders and cerebrovascular accidents, which may
prevent follow-up visits.
• A history of major psychiatric illness and/or poor cognitive function
precluding the giving of informed consent.
• History of severe gastro-intestinal disease and/or malabsorption that
may hinder the absorption of active ingredients from the
gastro-intestinal tract.
• Known allergy to one of the active ingredients, or other excipients in
the study preparation.
Ophthalmic conditions
• History of ophthalmic disease in the study eye, such as glaucoma
and diabetic maculopathy.
• History of retinal laser therapy in the proposed study eye.
Supplement use
• Prior and concurrent use of non-study preparation supplements
containing vitamin C and E, Zn, L and Z.*
*Participants consuming vitamins or natural/herbal remedies that are
not constituents of the CARMA preparation are eligible to participate in
the CARMA Study. The screening/baseline examination is conducted
after a washout period of 3 months.
the test to ensure correct alignment was maintained, as this can
influence target visibility.
Contrast sensitivity
Contrast sensitivity is measured for each eye using Pelli-
Robson contrast sensitivity charts (Clement Clarke Interna-
tional, Harlow, UK) viewed at a 1-m distance, and with + 0.5
diopter addition to the participant’s refractive correction. The
right and left eye is tested with the chart having V, R, S and
H, S, Z as the first triplet, respectively. Care is taken to ensure
uniform illumination of the chart, with luminance ranging from
60 to 120 foot-candles, and to conceal the chart from viewing
until the participant is ready for testing. Recording of contrast
sensitivity on a score-sheet is done in a manner similar to the
recording of VA.
Hyperacuity
Hyperacuity is assessed using the recently developed shape
discrimination charts consisting of radial frequency patterns as
the test targets.37 The test is performed under room lighting
conditions at standard viewing distance (38 cm) with reading
correction in place. As with contrast sensitivity, the participant
is encouraged to guess the deformed circle when the task is
perceived as being too difficult.
Anterior and posterior segment examination
A comprehensive slit lamp biomicroscopic examination is
performed after pupillary dilation. Anterior segment exami-
nation consists of a standardized detailed examination of the
cornea, the anterior chamber, and the lens. Lenticular opacities
are graded using Lens Opacities Classification Systems II.38
Fundus examination involves identification of AMD lesions,
such as drusen (type, number, and location) and/or pigmentary
changes (type, location, and nature). Participants requiring in-
tervention for recent evidence of neovascular disease and any
detected eye diseases (such as advanced cataract) are referred to
the principal investigator at the site for further management.
Macular pigment measurement
Macular pigment is measured using Raman spectroscopy,
which is an objective and non-invasive technique of measuring
MP in vivo.39,40 Detailed information of principle, apparatus,
and procedure, has been described elsewhere.41
Anterior and posterior segment photography
The anterior and posterior segments are photographed using
a digital Topcon Fundus Camera (Topcon TRC-50EX, Topcon,
Newbury, UK). Anterior segment images are graded for iris color
and lenticular opacities. The posterior segment images, which
consist of two non-simultaneous stereoscopic pairs centered on
the macula with a 35-degree field, are obtained after full pupil-
lary dilation. All images are stored as uncompressed tagged im-
age files, copied to compact discs and send to the grading center,
on a monthly basis.
Reading center fundus grading
Stereoscopically captured color retinal images are classified
and graded in a masked fashion by any one of the five graders
(who have completed the grader training and concordance ex-
ercises for the CARMA Study) using definitions of Wiscon-
sin Age-Related Maculopathy Grading System (WARMGS) for
early and late AMD features.42 The training for graders was
provided in-house using a structured training program along
with external qualified photo graders from the Wisconsin Fun-
dus Photograph Reading Centre and the Complications of AMD
Treatment Reading Centre. Concordance exercises were car-
ried out between Reading Centre Graders and representatives
from the above institutions. Ongoing quality assurance assess-
ments demonstrate that our inter-observer agreement values are
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comparable to past studies43 including one from our Reading
Centre.44
Fundus photographs are sent to the senior grader and Reading
Centre Clinician for adjudication in cases where a grader is not
100% confident of the AMD features to be graded. Ten percent
of gradings are randomly selected to be re-graded, and any dis-
crepancies are arbitrated by the Reading Centre clinician. As the
CARMA Study is a longitudinal study, changes in morphologi-
cal features of AMD are monitored over time, and in any fundus
photograph where progression or regression to a different stage
of AMD is deemed to have occurred, the images are routinely
checked by a senior grader.
General examination
The general physical examination consisted of measurement
of ambulatory blood pressure and body mass index.
Blood sample collection
For each participant, a peripheral venous blood sample of
20 ml is obtained. The participants are non-fasting; however,
they are requested not to take study medication, fruit or fruit
juices on the day of blood sample collection. Blood samples
are centrifuged within four hours of collection (3000 rpm, 15
minutes), and the resultant serum and plasma layers are aliquoted
into 12 micro centrifuge tubes and stored at −70 degree Celsius
(serum tubes: 4; plasma tubes: 4; vitamin C tubes: 2; DNA tubes:
2). The two micro centrifuge tubes, which are used for estimation
of vitamin C, consist of 100 µl plasma stabilized with 900 µl
of 5% metaphosphoric acid (which is freshly prepared weekly).
Buffy coats (collected at a single visit only) are stored in 2
micro centrifuge tubes for future genetic studies. Serum samples
packed in dry ice are shipped to the central laboratory on a 3-
monthly basis where they are stored at −70 degree Celsius until
analyzed by reverse-phase high pressure liquid chromatography.
Questionnaires
The general life-style and food frequency questionnaire are
administered during the baseline visit. The former gathers infor-
mation relating to socio-demographic details, smoking habits,
past medical history, use of aspirin and other prescription/or
over-the-counter medications, and in women a reproductive his-
tory including hormone replacement therapy is included.
A validated semi-quantitative food frequency questionnaire
evaluates the dietary intake for each participant for the 12
months immediately preceding the date of randomization(Willet
W. Nutritional Epidemiology. Oxford: Oxford University Press,
1990). The questionnaire comprises a list of 147 food items
which are divided into 12 sections: meat, fish,bread and
savory biscuits, cereals, rice and pasta, dairy products, fats and
dressings, sweets and snacks, soups and sauces, drinks, fruits,
vegetables. The options for frequency of consumption are
provided for each food item, and quantified in appropriate units
with reference to standard portion sizes. At baseline, the dietary
intake of L and Z will be assessed in both the intervention and
in the control group.
Randomization
Each participant enrolled in the CARMA Study is allo-
cated a unique number, which determines treatment allocation
according to the computerized randomization database. This
unique number exists on the identification label of each study-
preparation box. The masked study-preparation boxes are kept
in the hospital pharmacy, and released in a sequential manner by
the pharmacist on randomization of each participant, beginning
with the first in the numerical series assigned to each clinical
center. The participants are advised to take 1 tablet twice daily
with a meal.
The CARMA Study is strictly a double-masked clinical trial
in that neither the CARMA participants nor the study staff, in-
cluding the study investigator, are aware of the nature of study
preparation allocated to the participants. To ensure masking, the
study-preparation boxes are labeled with pre-assigned numbers
at the site of manufacturing, and then shipped to both clini-
cal centers for distribution. A single pharmacist involved with
manufacturing of the study preparation holds the key to random-
ization of the CARMA supplements.
Summary of the baseline data
In the CARMA Study, we have enrolled 433 participants,
with 237 (55%) and 196 (45%) in groups 1 and 2, respectively.
The mean age of the study population (± SD) was 75.93 ± 7.74
years, ranging between 50 and 95 years. Of the 433 participants,
248 (57%) were females and 185 (43%) were males.
At baseline visit, the mean (± SD) logMAR VA was compa-
rable in the two groups [Group 1 = 0.08 ± 0.12 (range: −0.3
to 0.3); Group 2 = 0.08 ± 0.14 (range: −0.2 to 0.5)]. Similarly,
there was no significant difference in total number of logMAR
letters recognized by the participants belonging to the two groups
[Group 1: = 50.80 ± 6.43 (range: 36 to 67); Group 2 = 50.60
± 7.44 (range: 29 to 65)].
Follow-up visits
Follow-up visits occur at 6 monthly intervals, with telephone
contact occurring at 2-weeks and at 3-months. The scheduling of
the follow-up visit at the study center is determined by the date of
randomization ± 7 days. At repeat study visits, the clinical and
ophthalmic assessments are repeated (Fig. 2). Information on
intercurrent illness, changes in regular medication and potential
adverse events, are recorded on a standardized proforma. At the
conclusion of the study visit, a further 6-month supply of the
study preparation is provided, and the importance of adherence
with the study protocol is re-emphasized to participants.
The compliance with study-preparation is assessed as fol-
lows: self-reporting the precise number of left-over tablets by
2-weekly and 3-monthly telephone contacts; tablet count of the
returned study-preparation box at each follow-up visit.
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        3-Month Telephone Check 
Enquire Compliance 
Enquire Adverse Event, if any
Enquire Quantity of Study 
preparation  
        
        Not Eligible 
Fundus Photography 
  Discharge
       Screening Visit 
Informed Consent 
Refraction  
Distance Visual Acuity 
Contrast Sensitivity 
Hyperacuity 
General & Dietary Questionnaire 
Ophthalmic Examination 
         
        Eligible 
Visometery 
Raman Spectroscopy  
Venepuncture and blood sampling 
Lens & Fundus Photography 
Randomization to Study preparation  
Potentially Eligible
Patients 
        
        Follow up Visits (6 monthly) ≤ 4 years 
Refraction  
Distance Visual Acuity 
Contrast Sensitivity 
Hyperacuity
Ophthalmic Examination 
Visometery 
Raman Spectroscopy 
Venepuncture and blood sampling 
Lens & Fundus Photography 
Collection of study preparation Box  
Dispense Study preparation & 
        Assess Adherence 
Recording of Adverse Event, if any
        
        Last Visit (Exit Visit) 
Refraction  
Distance Visual Acuity 
Contrast Sensitivity 
Hyperacuity
Ophthalmic Examination 
Visometery 
Raman spectroscopy 
Venepuncture and blood sampling 
Lens & Fundus Photography 
Collection of Study preparation Box  
Recording of Adverse Event, if any
Completion of Exit Form 
         
        Unscheduled Visit 
Refraction  
Distance Visual Acuity 
Contrast Sensitivity 
Hyperacuity 
Ophthalmic Examination 
Visometery 
Raman spectroscopy 
Venepuncture and blood sampling 
Lens & Fundus Photography 
Recording of Adverse Event, if any
        2-Week Telephone Check 
        2-Week Telephone Check 
Enquire Compliance 
Enquire Adverse Event, if any
Enquire Quantity of Study 
preparation 
        3-Month Telephone Check 
        Unscheduled Visit 
Figure 2. Overview of study visits for CARMA patients.
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Withdrawal and termination of followup visits
Participants are encouraged to adhere to the study protocol.
However, where a participant wishes to discontinue his/her par-
ticipation in the CARMA Study, whether voluntarily or because
of intercurrent medical indication (such as development of se-
vere systemic illness which preclude the participant from con-
tinuing the study preparation or attending the follow-up visits),
an exit visit is scheduled. During this visit, a clinical and oph-
thalmological assessment with photography is undertaken and
an exit form (stating the reason for his/her premature exit from
the study) is completed. Participants who are withdrawn from
the study are not replaced, and their identification numbers are
not reassigned.
Unscheduled visits
Unscheduled visits are conducted at the discretion of the in-
vestigator, and the information collected during such visits is
recorded on the Unscheduled Visit Forms. If a participant wishes
to discontinue at an unscheduled visit, the exit form is also com-
pleted.
Study preparation
The study preparation, manufactured by Bausch and Lomb
(Berlin), consists of either placebo or L (6 mg), Z (0.3 mg),
and co-antioxidants (vitamin E: 7.5 mg; vitamin C: 75 mg;
zinc: 10 mg; copper: 0.2 mg) as main ingredients in a tablet.
Beta-carotene, a carotenoid with antioxidant properties, is not
included in the study preparation, as there is an increased risk
of lung cancer in smokers who take supplements containing
beta-carotene.45,46 The placebo preparation consists of cellulose
microcrystalline, lactose, and magnesium stearate, and are in-
distinguishable from the intervention preparation in size, color,
smell, and taste. The study preparation is produced according
to Good Medical Practice as laid down in relevant European
directives, and currently has a shelf life of 24 months.
All the main ingredients of the study preparation belong to
the vitamin/micronutrient group, which are found in a typical
diet. Therefore, it is expected that the study preparation should
be well tolerated, and no side effects are anticipated when used
according to the study protocol, although mild gastro-intestinal
irritations may occur in a small number of participants. Allergic
reactions against the main ingredients or other excipients of the
study preparation may occur.
Safety of lutein and zeaxanthin
Three studies have investigated L toxicity in animal models,
and the data from these studies demonstrate that there have been
no adverse clinical or histopathological changes suggestive of
toxicity, following administration of high doses of L (up to 20
mg L/kg body weight/day for 52 weeks).47−49 Furthermore, a
number of human interventional studies, involving supplemen-
tation with high doses of L for extended periods of time, have
failed to demonstrate any toxicity in ocular and non-ocular tis-
sues (20 mg of L per day for 6 months).50−53 The only side effect
reported as a result of L supplementation in humans has been
carotenedermia, a harmless and reversible cutaneous hyperpig-
mentation, which is not associated with any specific adverse
effect on health.54−56
Adverse events
If an adverse event is detected or reported at any stage in the
study, an adverse event form is completed within five days of
the investigator being made aware of such an event. This form
contains information on the event, with particular attention di-
rected towards the date of onset, description of event, severity,
possible explanation, date of resolution (if any), relationship to
the study preparation, and the action taken with the study prepa-
ration. If an adverse event is believed to be attributable to the
study preparation (such as an allergic reaction), the participant
is advised to discontinue the study preparation, immediately and
permanently.
Every attempt is made to classify the event into a severe
adverse event or an adverse event, this categorization being con-
sistent with the ICH guidelines (Definitions and Standards for
Expedited Reporting, 2003). In the event of death, the medical
records, including the details of death certification, are obtained,
where available, to allow determination of the cause of death
and its relationship, if any, with the study preparation. All ad-
verse events are reported to the health authorities concerned. It
is mandatory to report serious adverse events within a timeframe
of 7 days of the principal investigator being notified of such an
event.
Outcome measures
The primary outcome variable is a change in the DVA of
the study eye at 12 months of antioxidant supplementation. The
level of significance for a change in DVA was set at 0.05. The
secondary outcome measures include retinal visual acuity, mor-
phological progression of AMD, MP levels, and serum levels of
antioxidants. Morphological status of AMD is based on detailed
grading of stereoscopic color fundus photographs.
The development of CNV or central GA is considered end
stage disease, and if reached, will be handled as follows: In
group 1, participants will exit the study if CNV or central GA
develops in the sole study eye. In group 2, where both eyes
are study eyes, the development of CNV or central GA in one
eye only is not a reason to exit the study, and the participant
remains in the study unless the second eye also develops end
stage disease. Participants who develop CNV during the course
of study are referred to the principle investigators for appropriate
management.
DATA ANALYSIS
In the present study, the main outcome DVA (expressed
in units which are the logarithm of the minimum angle
of resolution) will be measured as the average change in
DVA across the number of eyes recruited to the study. The
weights assigned to each participant will be obtained from
Ophthalmic Epidemiology November–December 2008 397
O
ph
th
al
m
ic
 E
pi
de
m
io
l D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Sw
et
s I
nf
or
m
at
io
n 
Se
rv
ic
es
 
Fo
r p
er
so
na
l u
se
 o
nl
y.
the formula suggested in the study protocol, and is expanded
below.
Handling of data from Group 2 participants
Several papers mention the lack of statistical independence
when dealing with outcomes in paired organs. This is a particu-
lar problem in ophthalmology as the outcomes measured in both
eyes of an individual are likely to be more closely related than
outcomes measured on eyes from different individuals. Earlier
reports have examined dichotomous outcomes, and so the solu-
tion becomes a particular application of intra-class correlation.
In this study, the main outcome, DVA, will be treated as contin-
uously distributed. One possible solution is simply to use data
from one eye only from participants in whom both eyes fit the
entry criteria. This method imposes a strict one eye per partici-
pant regime. The disadvantage of this approach is that it does not
utilize all readily available data, and is therefore cost inefficient.
Collecting all data and treating them as independent outcomes
can also be flawed for reasons stated above. A compromise so-
lution is suggested that follows parallel arguments to that for
intra-class correlation.57
Group 1 participants will only have one study eye (the fellow
eye having already been lost to exudative AMD). Let the variance
associated with change in DVA in this group be σ 21 . Group 2
participants may have both eyes eligible for the study, and thus
have two components of variance that can be estimated. That
between participants will be denoted σ 22B and that between eyes
within the same participant be σ 22W. In practice the study will
yield some large sample estimators s21, s
2,
2B and s22W. A reasonable
prior expectation might be for homogeneity of variance across
all participants, where σ 21 = σ 22B + σ 22W.
However, the approach suggested above will permit hetero-
geneity of variance between groups. It is usual, in situations
of heterogeneity of variance, to weight cases by the reciprocal
of the variation associated with each case. We propose, there-
fore, that all data be collected and the variance estimates de-
scribed above calculated. Data will be aggregated to one result
per participant—the sole result will stand for group 1 partici-
pants, and the mean of the two results will be applied to group 2
participants. The variance associated with group 1 participants
will be s21, while that associated with the mean of group 2 par-
ticipants will be s22B+ s22W/2. Therefore, in the main analysis,
group 1 participants will be given a weight of 1, whereas group
2 participants will be given a weight: w2 = s21/( s22B+ s22W/2).
We note that if most of the variation lies between participants,
then w2 will tend to be close to 1. Here, the second eye from
group 2 participants provides very little additional information.
However, if most of the variation lies within participants, then
w2 will tend to be close to 2. In this situation, the second eye
from participants in group 2 contributes additional information,
and we are moving towards a situation where both eyes of a
participant have been entered as independent observations. It is
important to note this approach is essentially weighted by recip-
rocal of the variation associated with each observation, which is
among the most common weighting strategies.
Analysis of primary outcome
These data will be analyzed by an independent samples t-test
with arm of the study as grouping variable. All tests will be
performed as 2-tailed hypotheses, and a p-value of 0.05 will be
regarded as statistically significant. For the purposes of analysis,
eyes with extremely poor vision i.e., worse than 1.6 logMAR will
be allocated a score of 1.7, and we do not intend to differentiate
between hand movements and light perception.
Adjustment for covariates
Distance VA, as defined above at 12 months after random-
ization into the trial, will be regressed on DVA at baseline, with
study group to which randomized as main factor, and linear ad-
justments allowed for variables (variable types) defined below:
• Gender (dichotomous)
• Age (continuous)
• Bilateral involvement (dichotomous)
• Smoking status (categorical)
• Eye color (categorical, but probably dichotomized)
• Use of vitamin supplements and/or diet at baseline (continu-
ously distributed).
ANALYSIS OF SECONDARY OUTCOMES
This will depend on the type of variable. Categorical variables
will be analyzed by chi-squared or Fisher’s Exact tests (the latter
being employed when expected counts drop close to or below
5.0). Continuously distributed variables will be analyzed by in-
dependent sample t-tests, after assessment of whether equal or
unequal variances can be assumed. Adjustment for covariates
will be performed when appropriate, and by logistic regression
for dichotomized categorical variables, and linear regression for
continuously distributed outcomes. Tests for heterogeneity of
variance and parallelism will be employed to check the validity
of these models. Transformations will be attempted when the
usual assumptions fail.
In this study, it is not expected that many outcomes will be
of an ordinal nature. However, if because of failed distribu-
tional assumptions, continuously distributed variables have to
be transformed to ordinal scales, then the module for ordinal
regression will be employed along with tests for parallelism.
Although some secondary outcomes such as CS, like distance
VA, will be assessed at the level of eye, such outcomes will be
combined by the method suggested above, and the analysis will
continue with the experimental unit as a single participant and
using appropriate statistical methods.
QUALITY CONTROL
Various steps are taken to ensure adequate quality control
for the CARMA Study. First, a comprehensive study manual,
with detailed and clear instructions for carrying out the study
procedures is available. Second, study staff at the two centers
work to agreed protocols. Third, both centers are equipped with
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identical instruments which are calibrated to agree preset stan-
dards. Fourth, the eligibility criteria are verified by an examin-
ing ophthalmologist at the screening visit before randomization.
Where eligibility is in question, adjudication by both principal
investigators is used to determine the ultimate eligibility of the
patient. Fifth, centralized data management facilitates scrutiny
of the CRF for completeness and consistency, with queries re-
solved rapidly. Finally, regular monitoring and quality control
is undertaken by the coordinating center.
SAFETY AND DATA MONITORING
COMMITTEE
An independent DSMC scrutinizes the unblinded data for ev-
idence of safety and efficacy every year. This committee com-
prises of three internationally recognized scientific and clinical
members (two ophthalmologists and one physician epidemiol-
ogist), and has the power to recommend any of the following;
continuation of the study uninterrupted, alteration of the study
or any arm of the study, or termination of the study or any arm
of the study.
DISCUSSION AND EXPECTED
CONTRIBUTION
The CARMA Study is an important interventional study
of antioxidant supplementation in AMD patients. Similar to
AREDS II,58 the CARMA Study is a randomized, double
masked, and placebo controlled clinical trial of L and Z along
with co-antioxidants in AMD participants with a reasonably
good sample size. However, the CARMA supplement does not
include omega 3 poly-unsaturated fatty acids, which are increas-
ingly believed to play a protective role in AMD.
Furthermore, and similar to the LAST trial,30 the CARMA
Study is examining the effect of antioxidant supplementation
on psychophysical visual function, such as DVA, contrast sen-
sitivity, and retinal visual acuity. However, in the LAST trial,
the study population consisted of 90 male participants with ad-
vanced AMD (atrophic) and at least one vision-degrading psy-
chophysical abnormality. Whereas, in the CARMA Study, 248
females and 185 males with either early AMD features of suf-
ficient severity in at least one eye or any level of AMD in one
eye and advanced AMD in the fellow eye have participated.
Also, the OcuPower supplement in the LAST trial consisted of
a large number of nutrients in contrast to the CARMA supple-
ment, which contains 5 major antioxidants, including L and Z
that constitute MP.
The CARMA Study will provide invaluable and timely data
on the potential role of antioxidants, including L and Z, in de-
laying AMD progression. An observed beneficial effect of such
intervention will complement evidence from other completed
and ongoing randomized clinical trials, and inform current prac-
tice with respect to the role of dietary modification and/or sup-
plementation in patients with AMD. The CARMA Study will
also yield valuable information with respect to visual function
and MP levels following supplementation with L, Z, and an-
tioxidants in eyes with AMD. Finally, the CARMA Study will
provide data on the safety and toxicity of L, Z, and antioxidant
supplementation in human subjects.
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